Table 1:

Effect of Atorvastatin on Primary and Secondary Outcomes of Insulin Resistance and Insulin Secretion (N=71^*)

Variable	Baseline	End of Study	P value†
Primary Outcomes
Insulin Suppression Test
Insulin Resistance (by SSPG, mg/dL)	130 (85 – 193)	139 (93 – 211)	0.01
SSPI, mU/L	64.7 (54.6 – 75. 4)	61.3 (55.7 – 71.4)	0.02
Graded Glucose Infusion Test
Insulin secretion (by ISRAUC, pmol/min x 4 h)	1824 (1385 – 2549)	1942 (1480 – 2755)	<0.001
GlucoseAUC, mmol/L x 4 h	31.2 (28.0 – 34.5)	31.8 (28.4 – 34.7)	0.10
InsulinAUC, pmol/L x 4 h	652 (430 – 1108)	712 (458 – 1263)	0.001
C-peptideAUC, nmol/L x 4 h	6.5 (4.9 – 8.3)	6.5 (5.3 – 8.9)	<0.001
Secondary Outcomes
Fasting glucose, mg/dL	99 (92 – 108)	100 (94 – 107)	0.10
Fasting insulin, mU/L	10.1 (7.3 – 14.8)	10.6 (7.6 – 15.1)	0.01
HOMA-IR	2.44 (1.71 – 3.73)	2.68 (1.81 – 4.07)	0.01
OGTT GlucoseAUC, mg/dL x 2 h	295 (241 – 336)	299 (254 – 339)	0.03
OGTT InsulinAUC, mU/L x 2 h	127 (74 – 217)	133 (88 – 218)	0.27

Data are median (interquartile range).

^*SSPG (N=70); SSPI (N=66), ISR_AUC, Glucose_AUC, Insulin_AUC, and C-peptide_AUC (N=64); fasting insulin and HOMA-IR (N=69); and OGTT Insulin_AUC (N=64).

All variables were log-transformed except fasting glucose and glucose_AUC.

^†Paired sample t tests were used to compare baseline and end-of-study means.

AUC indicates area under the curve; HOMA-IR, homeostasis model assessment of insulin resistance; ISR, insulin secretion rate; OGTT, oral glucose tolerance test; SSPG, steady-state plasma glucose; and SSPI, steady-state plasma insulin.